Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

8 Jun 2010

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

PTC Therapeutics, Inc. today announced the receipt of a $5.4 million Seeding Drug Discovery Award from The Wellcome Trust to support the development of drugs that target Bmi-1, a protein that has been linked to drug resistant cancers.

7 Jun 2010

Cytheris completes €12 million Series D financing

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has completed a €12 million ($15 million) Series D financing.

7 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

7 Jun 2010

Positive phase III clinical trial data of NovoCure's NovoTTF device for recurrent GBM presented at ASCO

Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.

7 Jun 2010

ASTRO to honor David Larson and William McBride with prestigious Gold Medal award

David Larson, M.D., Ph.D., FASTRO, and William McBride, D.Sc., Ph.D., have been chosen to receive the American Society for Radiation Oncology's most prestigious award, the Gold Medal. They will be presented with this honor at the Awards Ceremony during ASTRO's 52nd Annual Meeting, taking place October 31 to November 4, 2010, in San Diego.

4 Jun 2010

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

Men who refuse surgery for prostate cancer and instead opt for "watchful waiting" - monitoring cancer progression without undergoing treatment - have a significantly worse long-term survival rate than those patients that choose radiotherapy, according to researchers at Henry Ford Hospital in Detroit.

2 Jun 2010

TU Delft, MI Labs combine microPET and microSPECT into Versatile Emission Computed Tomography device

TU Delft and Molecular Imaging Labs (MI Labs) have succeeded in combining two forms of medical imaging techniques into one piece of equipment. These techniques are particularly useful for cancer research.

2 Jun 2010

Elekta acquires Resonant Medical

Elekta today announced the acquisition of Resonant Medical Inc., Montreal Canada. Through this acquisition, Elekta adds exciting new solutions for image guidance as well as highly skilled R&D resources in the field of oncology imaging and motion management.

From Elekta 1 Jun 2010

IMRT avoids xerostomia, but effectiveness on controlling cancer unclear

An advanced type of cancer radiation is more successful than traditional radiation in avoiding "dry mouth" when treating head and neck cancers, but it is unknown whether the treatment is better or worse at reducing the size of tumors, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

31 May 2010

EDAP to showcase Ablatherm-HIFU technology and Sonolith i-sys lithotripter at AUA 2010 Annual Meeting

EDAP TMS SA, the global leader in therapeutic ultrasound, today announced it will have a strong presence in both the exhibition and the scientific program at the American Urological Association (AUA) 2010 Annual Meeting, being held May 29 – June 3, 2010 in San Francisco. EDAP will showcase its Ablatherm-HIFU technology and Sonolith i-sys lithotripter at its exhibition booth # 1938 of the Moscone Convention Center.

29 May 2010

Aggressive treatment of anaplastic thyroid carcinoma increases survival: Study

Aggressive treatment of anaplastic thyroid carcinoma has dramatically increased survival in the small group of patients who chose to undergo it, say physicians at Mayo Clinic. Their findings will be presented at the annual meeting of the American Society of Clinical Oncology, to be held June 4-8 in Chicago.

28 May 2010

IMRT leads to fewer cases of xerostomia than other types of radiation: AHRQ report

28 May 2010

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.

27 May 2010

Concord Medical first-quarter total net revenues increase 36.6% to $11.2 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited financial results for the first quarter ended March 31, 2010.

27 May 2010

Nottingham scientists given green light to test new vaccine for malignant melanoma

Nottingham scientists have been given the green light to test a vaccine which they hope could reverse, and even cure malignant melanoma, the most deadly type of skin cancer.

27 May 2010

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy in Washington, DC (May 17 - 22, 2010).

25 May 2010

Researchers identify cancer gene that could help fight paediatric glioma

Researchers have identified an important cancer gene that could lead to more effective drugs being developed to fight paediatric high grade glioma, a disease which currently has a poor prognosis.

19 May 2010

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Oncolytics Biotech Inc. announced today that a paper entitled "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," has been published in the online version of the journal Clinical Cancer Research.

19 May 2010

Radiotherapy News and Research

Further Reading

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

Cytheris completes €12 million Series D financing

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Positive phase III clinical trial data of NovoCure's NovoTTF device for recurrent GBM presented at ASCO

ASTRO to honor David Larson and William McBride with prestigious Gold Medal award

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

TU Delft, MI Labs combine microPET and microSPECT into Versatile Emission Computed Tomography device

Elekta acquires Resonant Medical

IMRT avoids xerostomia, but effectiveness on controlling cancer unclear

EDAP to showcase Ablatherm-HIFU technology and Sonolith i-sys lithotripter at AUA 2010 Annual Meeting

Aggressive treatment of anaplastic thyroid carcinoma increases survival: Study

IMRT leads to fewer cases of xerostomia than other types of radiation: AHRQ report

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

Concord Medical first-quarter total net revenues increase 36.6% to $11.2 million

Nottingham scientists given green light to test new vaccine for malignant melanoma

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Researchers identify cancer gene that could help fight paediatric glioma

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News